Timber Pharmaceuticals, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) operates as a clinical-stage biopharmaceutical company and wholly-owned subsidiary of LEO Pharma focused on developing and commercializing non-systemic topical treatments for orphan and rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and sclerotic skin diseases such as scleroderma; its pipeline features TMB-001 (topical isotretinoin ointment for moderate to severe congenital ichthyosis), TMB-002 (topical rapamycin for facial angiofibromas), TMB-003 (topical or subcutaneous endothelin-A receptor antagonist for scleroderma), and legacy assets BPX-01 and BPX-04 (topical minocycline formulations for acne vulgaris and papulopustular rosacea). Founded in 2019 and headquartered in Madison, New Jersey, the company targets underserved patient populations in medical dermatology with therapies leveraging proven mechanisms and established safety profiles. In January 2024, LEO Pharma finalized its acquisition of TMB-001 and select assets from Timber following the company's Chapter 11 bankruptcy filing and reorganization, integrating Timber as a subsidiary while providing debtor-in-possession financing to support operations; in August 2024, Timber announced that the Phase 3 ASCEND trial for TMB-001 missed primary and key secondary endpoints due to high vehicle response, precluding a New Drug Application submission to the FDA.
MSG Networks in talks to avoid bankruptcy — possibly with help of Amazon: sources
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
Timber Pharmaceuticals to be Acquired by LEO Pharma
Timber Pharmaceuticals Discloses Communication From NYSE American
Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001
Bears are Losing Control Over Timber Pharmaceuticals, Inc. (TMBR), Here's Why It's a 'Buy' Now
Building a Penny Stocks Portfolio For Long Term
Penny Stock Investing: How to Analyze Market Conditions
Why Is Timber Pharmaceuticals (TMBR) Stock Up 61% Today?